EA201491851A1 - Композиции и способы для лечения болезни альцгеймера - Google Patents

Композиции и способы для лечения болезни альцгеймера

Info

Publication number
EA201491851A1
EA201491851A1 EA201491851A EA201491851A EA201491851A1 EA 201491851 A1 EA201491851 A1 EA 201491851A1 EA 201491851 A EA201491851 A EA 201491851A EA 201491851 A EA201491851 A EA 201491851A EA 201491851 A1 EA201491851 A1 EA 201491851A1
Authority
EA
Eurasian Patent Office
Prior art keywords
seq
antibodies
fragments
amino acid
alzheimer
Prior art date
Application number
EA201491851A
Other languages
English (en)
Inventor
Нейл Р. Кэшман
Грант Маккларти
Original Assignee
Канджин Ю.С., Инкорпорейтед
Зе Юниверсити Оф Бритиш Колумбия
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Канджин Ю.С., Инкорпорейтед, Зе Юниверсити Оф Бритиш Колумбия filed Critical Канджин Ю.С., Инкорпорейтед
Publication of EA201491851A1 publication Critical patent/EA201491851A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Pathology (AREA)
  • Psychiatry (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Hospice & Palliative Care (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

В изобретении предложен гипериммунный препарат, который содержит поликлональные антитела человека или фрагменты указанных антител, специфичные к циклическому пептиду, имеющему аминокислотную последовательность, которая содержит SNK. Циклический пептид может содержать аминокислотную последовательность GSNK (SEQ ID NO: 1), SNKG (SEQ ID NO: 2), GSNKG (SEQ ID NO: 3), CSNKG (SEQ ID NO: 4), CGSNKGC (SEQ ID NO: 5), CGSNKGG (SEQ ID NO: 6) или CCGSNKGC (SEQ ID NO: 7). Титр антител в указанном гипериммунном препарате может составлять от приблизительно 200 до приблизительно 400 единиц средней интенсивности флуоресценции. Согласно одному варианту реализации изобретения более чем приблизительно 80% антител в указанном гипериммунном препарате представляют собой IgG. Фрагменты указанных антител представляют собой Fab, F(ab'), scFv, связанный дисульфидными связями Fv или смеси указанных фрагментов.
EA201491851A 2011-11-10 2012-11-12 Композиции и способы для лечения болезни альцгеймера EA201491851A1 (ru)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201161558430P 2011-11-10 2011-11-10
US201261589809P 2012-01-23 2012-01-23
US201213582308A 2012-08-31 2012-08-31
PCT/US2012/064722 WO2013071267A1 (en) 2011-11-10 2012-11-12 Compositions and methods for treating alzheimer's disease

Publications (1)

Publication Number Publication Date
EA201491851A1 true EA201491851A1 (ru) 2015-12-30

Family

ID=48290671

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201491851A EA201491851A1 (ru) 2011-11-10 2012-11-12 Композиции и способы для лечения болезни альцгеймера

Country Status (8)

Country Link
EP (1) EP2780082A4 (ru)
CN (1) CN104093454A (ru)
AU (1) AU2012335014A1 (ru)
CA (1) CA2855669A1 (ru)
EA (1) EA201491851A1 (ru)
HK (1) HK1201771A1 (ru)
SG (1) SG11201403272YA (ru)
WO (1) WO2013071267A1 (ru)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112012022229A2 (pt) 2010-03-03 2016-07-05 Univ British Columbia epítopo beta amilóide epecíficio para oligômero e anticorpos
EP3102611A4 (en) * 2014-02-03 2017-08-23 Cangene Corporation Humanized beta-amyloid binding molecules and uses thereof
WO2016008047A1 (en) * 2014-07-14 2016-01-21 Cangene Corporation Cyclic peptide vaccination for treatment of amyloid beta-related disorders
WO2016187339A1 (en) * 2015-05-18 2016-11-24 Synaptec Development Llc GALANTAMINE CLEARANCE OF AMYLOIDß
WO2017079833A1 (en) * 2015-11-09 2017-05-18 The University Of British Columbia Epitopes in amyloid beta mid-region and conformationally-selective antibodies thereto
EP3374382A4 (en) * 2015-11-09 2019-05-15 The University Of British Columbia BETA-AMYLOID EPITOPES AND ASSOCIATED SELECTIVE CONFORMATIONAL ANTIBODIES
US20180346534A1 (en) * 2015-11-09 2018-12-06 The University Of British Columbia C-terminal epitopes in amyloid beta and conformationally-selective antibodies thereto
EP3374383A4 (en) * 2015-11-09 2019-05-15 The University Of British Columbia BETA-AMYLOID EPITOPES AND ASSOCIATED ANTIBODIES
WO2017079831A1 (en) 2015-11-09 2017-05-18 The University Of British Columbia N-terminal epitopes in amyloid beta and conformationally-selective antibodies thereto
US20180125920A1 (en) 2016-11-09 2018-05-10 The University Of British Columbia Methods for preventing and treating A-beta oligomer-associated and/or -induced diseases and conditions
US10259865B2 (en) * 2017-03-15 2019-04-16 Adma Biologics, Inc. Anti-pneumococcal hyperimmune globulin for the treatment and prevention of pneumococcal infection
CN112661828B (zh) * 2021-01-15 2022-04-01 武汉大学 一种突触素的抗原肽及其抗体与应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ590324A (en) * 2008-07-01 2012-08-31 Nederlanden Staat Vaccine against amyloid folding intermediate
US20110306605A1 (en) * 2008-12-22 2011-12-15 Sloan-Kettering Institute For Cancer Research Coumarin-based compounds for the treatment of alzheimer's disease and cancer
WO2011100292A1 (en) * 2010-02-09 2011-08-18 Bristol-Myers Squibb Company Immunoassay standards and measurement of clinical biomarkers using intra-assay calibration standards
BR112012022229A2 (pt) * 2010-03-03 2016-07-05 Univ British Columbia epítopo beta amilóide epecíficio para oligômero e anticorpos

Also Published As

Publication number Publication date
EP2780082A4 (en) 2015-08-05
EP2780082A1 (en) 2014-09-24
AU2012335014A1 (en) 2014-06-19
CA2855669A1 (en) 2013-05-16
SG11201403272YA (en) 2014-08-28
HK1201771A1 (en) 2015-09-11
CN104093454A (zh) 2014-10-08
WO2013071267A1 (en) 2013-05-16

Similar Documents

Publication Publication Date Title
EA201491851A1 (ru) Композиции и способы для лечения болезни альцгеймера
EA201490053A1 (ru) Антитела, которые связываются с ox40, и их применение
EA201190132A1 (ru) Гуманизированные антитела, связывающиеся с cd19, и их применение
EA201270813A1 (ru) АНТИТЕЛА К N3pGlu БЕТА-АМИЛОИДНОМУ ПЕПТИДУ И ИХ ПРИМЕНЕНИЕ
PE20181270A1 (es) Anticuerpo que neutraliza el virus respiratorio sincitial humano
EA201892793A1 (ru) Анти-hla-g специфические антитела
RU2014101707A (ru) АНТИ-Axl АНТИТЕЛА И ИХ ПРИМЕНЕНИЕ
PE20190737A1 (es) Anticuerpos anti-cd27
ES2776179T3 (es) Anticuerpos dirigidos contra determinantes de la superficie de S. aureus
PE20210377A1 (es) Anticuerpos anti-pd-l1 y usos de los mismos
PE20071055A1 (es) Anticuerpos anti mn
UA117901C2 (uk) Спосіб посилення ефекторної функції вихідного поліпептиду, його варіанти та їх застосування
PE20120475A1 (es) Anticuerpos especificos para dkk-1
EA201591091A1 (ru) Антигенсвязывающие белки для bcma
EA201591153A1 (ru) Антитела, связывающиеся с tl1a, и их применение
EA200970879A1 (ru) Связывающие белки, включающие антитела, производные антител и фрагменты антител, которые специфически связываются с cd154, и их применения
EA201291243A1 (ru) Антитела против респираторно-синцитиального вируса (рсв) и способы их применения
PE20141433A1 (es) Anticuerpos neutralizantes de citomegalovirus humano
NZ701444A (en) Antibodies to matrix metalloproteinase 9
NZ598202A (en) High affinity human antibodies to human angiopoietin-2
EA201490677A1 (ru) Связывающие антиген cd27l белки
CR20120027A (es) Polipeptidos y metodo de tratamiento
RU2017129721A (ru) АНТИТЕЛА ПРОТИВ αβTCR
MX341536B (es) Epitopo y anticuerpos beta amiloide de oligomero especifico.
EA200970694A1 (ru) ПЭГИЛИРОВАННЫЕ Fab-ФРАГМЕНТЫ АНТИТЕЛ К ПЕПТИДУ Aβ